Brain Tumor Diagnosis and Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing & EEG), By Application (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy & Targeted Therapy) and Regional Insights and Forecast to 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

BRAIN TUMOR DIAGNOSIS AND THERAPEUTICS MARKET REPORT OVERVIEW

The global Brain Tumor Diagnosis and Therapeutics Market size was USD 3.42 billion in 2025, and the market is projected to touch USD 7.56 billion in 2034, exhibiting a CAGR of 8.0% during the forecast period.

Brain Tumor Diagnosis and Therapeutics is the discipline that constitutes the important methodologies and technologies of the process of diagnosis and treatment of the abnormal growths of cells in the brain or in the proximity. To diagnose the disease, sophisticated neuroimaging procedures such as MRI and CT scans are important to mark and describe the tumor and may be accompanied by a tissue biopsy to perform strict grading and molecular study to determine genetic mutations. Therapy is also generally multimodal and highly individualised, where neurosurgery is frequently performed to remove as much of the lesion as possible, followed by different types of radiation (external beam radiation or highly targeted radiosurgery/proton therapy) and systemic therapy (such as chemotherapy).

COVID-19 IMPACT

Market Growth Restrained by Pandemic due to Disruption of Healthcare System

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market's growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic contributed to various detrimental effects on this market, with the most significant of them being the disruption of the healthcare system, which resulted in a significant reduction in the number of non-malignant brain tumor diagnoses as a result of delayed non-urgent appointments and the general unwillingness to visit a medical facility to find less serious symptoms. Although the prevention and violent treatment of highly aggressive tumors such as glioblastoma were predominantly given priority and focus, there were many adverse effects among the patient population, such as heightened psychological distress.

LATEST TRENDS

Precision Medicine to Propel Market Growth

The situation in this market is currently marked by an intense move towards precision medicine, which is occasioned by the incorporation of emerging technologies such as AI and molecular diagnostics. AI is transforming the diagnosis process through improving the accuracy and speed of neuroimaging and pathology analysis and providing faster and more tailored treatment planning. The market in therapeutics is growing quickly and concentrating on such advanced forms of therapies as immunotherapy and targeted therapy.

•   
•   
  

  Request a Free sample to learn more about this report

    

BRAIN TUMOR DIAGNOSIS AND THERAPEUTICS MARKET SEGMENTATION

By Type

Based on type the market can be categorized into MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing & EEG

• MRI: boasts of having significant market share in this segment, frequently being quoted as the leading imaging modality. It is a non-ionizing radiation technique, which is preferred to be used as a first-line approach in the diagnosis, characterization, and follow-up of brain tumors.

• CT scan: has a large market share in the field of diagnosis and treatment of brain tumors. It is a first-line diagnostic method, especially in an emergency, because it is fast, is widely available, and shows acute conditions (hemorrhage, mass effect, and calcification, etc.) within a short period of time.

• PET-CT scan: PET-CT is an essential ingredient of the diagnosis, and it belongs to a greater portion of the Positron Emission Tomography (PET) market in general, with the PET/CT modality occupying a major portion of the market of PET scanners.

• Tissue Sampling: Tissue sampling (biopsy) is a procedure to be performed as a part of diagnosis, although not a product (like the scanners). Within this wide market, a proportion of the market is comprised of the procedure segment (including surgery and biopsy) (e.g., surgery occupying an important market share).

• Molecular Testing: The molecular testing segment is noted to be the fastest-growing segment of diagnosis of brain tumors owing to the move to personalized medicine. This testing includes the analysis of the genetic composition of the tumor (DNA, RNA, and protein) with the determination of mutations and biomarkers.

• Cerebral Arteriogram (Angiography): This is not as often used in primary diagnosis but is essential in preoperative planning to map the blood supply of the tumor and embolize blood vessels, especially in vascular tumors.

• Lumbar Puncture: This procedure is required to analyze cerebrospinal fluid (CSF) in case of a suspicion of leptomeningeal spread (cancer cells in the fluid/linings) or CNS lymphoma.

• EEG: EEG is an experimental test that is carried out to evaluate seizure activity, which may either be a symptom or a complication of a brain tumor. It is not a major anatomical diagnosis tool but plays a role in the management of patients.

By Application

Based on application the market can be categorized into Surgery, Radiation Therapy, Chemotherapy, Immunotherapy & Targeted Therapy

• Surgery: in most cases, surgery constitutes the biggest market share of revenue in this market, historically controlling the market. An example here would be the fact that the surgery can contribute a significant amount of share, as it is often the first and most preferred mode of treatment in the case of operable tumors, where maximum safe resection of the tumor is attempted.

• Radiation therapy: is a vital and established market segment in this industry which is usually applied together with surgery or as a first-line intervention in some instances. It has the progressive methods such as intensity-modulated radiation therapy, stereotactic radiosurgery and proton therapy.

• Chemotherapy: The market share of chemotherapy is usually large, especially in the brain tumor drugs (therapeutics) segment. As a case in point, it was said to be leading in the market of brain tumor drugs with a share rate of about 36.4 in 2023.

• Immunotherapy: Immunotherapy is a fast-growing and dynamic market in the brain tumor therapeutics market and has one of the fastest Compound Annual Growth Rates (CAGR) among the applications.

• Targeted Therapy: Another high-growth segment is targeted therapy, one of which forecasts it to grow at the highest rate of 8.3% CAGR in the diagnosis and therapeutics market and one that predicts it as the fastest-growing category with an estimated CAGR of 8.52 in the therapeutics market.

MARKET DYNAMICS

Driving Factors

Innovation and Technology in Precision Medicine and New Therapies to Drive the Market Advancement

One of the major driving factors of the Brain Tumor Diagnosis and Therapeutics Market Growth because of the Innovation and Technology in Precision Medicine and New Therapies. One of the main factors is the swift progress of precision medicine that is changing the landscape of treatment by shifting to the highly personalized therapies. Genomic profiling and molecular diagnostics innovations can currently enable clinicians to detect genetic mutations and biomarkers that are unique to a particular patient tumor. Such vital information preconditions the creation and implementation of extremely effective targeted therapy (such as molecularly targeted drugs) and optimal treatment.

Increasing World Brain Tumor Incidence and Ageing to Expand the Market

The other major force is the rising worldwide prevalence of brain tumors, whether malignant or benign, that brings about the rising and urgent need to find successful diagnostic and treatment solutions. This growth has been associated more so with demographic changes, especially the increase in the ageing population, because older people are more likely to contract brain tumors. The very fact that the number of patients is swelling and the awareness of the symptoms and methods of treatment is growing motivates more individuals to seek early diagnoses and treatment.

Restraining Factor

Biological Barrier: Blood-Brain Barrier (BBB) to the Market Growth

The only constraint that has been challenging and enduring within this market is the existence of the blood-brain barrier (BBB), which is a very selective semipermeable membrane separating circulating blood and extracellular fluid of the brain. The natural role of the BBB is to isolate the central nervous system against the circulation of toxins and pathogens, which is, unfortunately, also applied to most therapeutic agents, especially large-molecule drugs such as most chemotherapies, antibodies, and novel targeted therapies.

Precision Medicine Technological Advances to the Market Growth

Opportunity

One of the opportunity factors that have propelled this market is the ever-growing and rapid development of precision medicine, especially targeted therapies and immunotherapies.

This trend is aided by increased knowledge on the molecular and genetic characterization of brain tumors, which has enabled the finding of treatments like specific kinase inhibitors and checkpoint inhibitors, which can specifically act on the cancer cells, unlike the standard chemotherapy.

Breaking the Blood-Brain Barrier and the Tumor Heterogeneity to Challenge the Market Growth

Challenge

The confluence of the blood-brain barrier (BBB) and aggressive genetic heterogeneity of the tumor per se is the most significant challenging factor in this market.

BBB is a very limiting biological process that does not allow most therapeutic drugs, particularly large-molecule and targeted drugs, to reach effective levels in the brain tissue to combat the tumor.

•   
•   
  Request a Free sample to learn more about this report

    

BRAIN TUMOR DIAGNOSIS AND THERAPEUTICSR MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

• North America

North America has emerged as the most dominant region in the Brain Tumor Diagnosis and Therapeutics Market share because it has been able to contribute more than 40 per cent of the total amount. There are various factors that have contributed to this leadership: the presence of a developed and mature healthcare system, expenditures on healthcare that are very high per capita, and an extraordinarily strong research and development (R&D) network. The U.S. is where substantial investment in oncology R&D is centered, and this is driving a robust pipeline of innovative treatment solutions such as immunotherapies, targeted therapies, and precision medicine solutions.

• Europe

The European market share is the second-largest market share of this treatment due to the well-assigned universal healthcare and the great extent of medical proficiency. Growth in the market is facilitated by the increased occurrence of brain tumors, ageing and the constant development of new technology in imaging and delivery of treatment, like improved methods of radiation and surgery. The development of a drug is facilitated by favorable regulatory policies such as Orphan Drug Designations by the European Medicines Agency in rare diseases such as most brain tumors. The major research and clinical trial neuro-oncology centers are located there, such as in Germany, France and the UK, which guarantees that new therapies are implemented, though at a slower rate than in the US because of varying price and reimbursement agreements by member states.

• Asia

This fastest-growing regional market is expected to be Asia-Pacific, as such countries as China, Japan and India are the main drivers of growth. This is an explosive increase owed to a huge and escalating patient population because of increasing incidence of cancer and an ageing population. The market is driven by the rising healthcare infrastructure and, particularly in the emerging economies, the rising healthcare spending and rising awareness of the sophisticated treatment solutions. Although the region still trails the West on the direct adoption of most costly novel drugs because of cost and less favorable reimbursement in certain locations, swift development in scientific capacity, adoption of Western treatment guidelines, and a significant increase in clinical trial rates make Asia the most vital future market in relation to therapeutic development and business size.

KEY INDUSTRY PLAYERS

Key Players Transforming the Brain Tumor Diagnosis and Therapeutics Landscape through Innovation and Global Strategy

The most significant industrial factor in this market is the speedy and unstoppable technological progress due to the large-scale enterprises of healthcare, pharmaceutical, and biotechnological facilities, as well as the increased funding in research and development. This industrial drive is aimed at the development of the next-generation diagnostic tools, including the advanced neuroimaging methods (e.g., AI-operated MRI and CT scans) to detect the tumours earlier and more precisely, as well as the creation of new therapeutic modalities, including targeted drug therapies, immunotherapies, and gene/cell therapies.

List Of Market Players Profiled

• GE Healthcare (U.S.)
• Hitachi (Japan)
• Philips Healthcare (Netherlands)
• Siemens Healthineers (Germany)
• Toshiba Corporation (Japan)

INDUSTRIAL DEVELOPMENT

August 6, 2025: The FDA accelerated the approval of Modeyso (dordaviprone), the first of its kind of treatment used to treat a highly aggressive and a very rare brain tumor in children. Jazz Pharmaceuticals plc declared this consent on August 6, 2025.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis considers both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.